These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7094504)

  • 21. Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment.
    Eichelbaum M; Birkel P; Grube E; Gütgemann U; Somogyi A
    Klin Wochenschr; 1980 Sep; 58(18):919-25. PubMed ID: 7206587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous first-order and capacity-limited elimination kinetics after oral administration of verapamil.
    Gupta SK; Hwang S; Atkinson L; Longstreth J
    J Clin Pharmacol; 1996 Jan; 36(1):25-34. PubMed ID: 8932540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man.
    Keech AC; Harper RW; Harrison PM; Pitt A; McLean AJ
    Eur J Clin Pharmacol; 1988; 35(4):363-6. PubMed ID: 3197744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleomycin disposition in children with cancer.
    Yee GC; Crom WR; Lee FH; Smyth RD; Evans WE
    Clin Pharmacol Ther; 1983 May; 33(5):668-73. PubMed ID: 6188571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inequality of clearance values obtained by intravenous bolus and by steady-state infusion. Prednisolone studies in dogs.
    Frey FJ; Frey BM
    Pharmacology; 1982; 24(6):346-54. PubMed ID: 7111375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration.
    Abernethy DR; Wainer IW; Anacleto AI
    Drug Metab Dispos; 2000 Jul; 28(7):760-5. PubMed ID: 10859149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in oral verapamil absorption as a function of time of day.
    Eldon MA; Battle MM; Voigtman RE; Colburn WA
    J Clin Pharmacol; 1989 Nov; 29(11):989-93. PubMed ID: 2600194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of the enantiomers of verapamil in the dog.
    Bai SA; Lankford SM; Johnson LM
    Chirality; 1993; 5(6):436-42. PubMed ID: 8398603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
    Kim HJ; Choi JS
    Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration.
    Dominic JA; Bourne DW; Tan TG; Kirsten EB; McAllister RG
    J Cardiovasc Pharmacol; 1981; 3(1):25-38. PubMed ID: 6160352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.
    Eichelbaum M; Somogyi A
    Eur J Clin Pharmacol; 1984; 26(1):47-53. PubMed ID: 6714292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers.
    Schwartz JB; Capili H; Wainer IW
    Clin Pharmacol Ther; 1994 Oct; 56(4):368-76. PubMed ID: 7955798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
    Tartaglione TA; Pieper JA; Lopez LL; Mehta J
    Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):15-27. PubMed ID: 6867470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.
    Eichelbaum M; Somogyi A; von Unruh GE; Dengler HJ
    Eur J Clin Pharmacol; 1981 Jan; 19(2):133-7. PubMed ID: 7202473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats.
    Egorin MJ; Yuan ZM; Sentz DL; Plaisance K; Eiseman JL
    Cancer Chemother Pharmacol; 1999; 43(6):445-53. PubMed ID: 10321503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiological disposition of verapamil in man.
    Schomerus M; Spiegelhalder B; Stieren B; Eichelbaum M
    Cardiovasc Res; 1976 Sep; 10(5):605-12. PubMed ID: 971476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates.
    Barbarash RA; Bauman JL; Fischer JH; Kondos GT; Batenhorst RL
    Chest; 1988 Nov; 94(5):954-9. PubMed ID: 3180898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single- and multiple-dose metronidazole kinetics.
    Jensen JC; Gugler R
    Clin Pharmacol Ther; 1983 Oct; 34(4):481-7. PubMed ID: 6617070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of verapamil in patients with renal failure.
    Mooy J; Schols M; v Baak M; v Hooff M; Muytjens A; Rahn KH
    Eur J Clin Pharmacol; 1985; 28(4):405-10. PubMed ID: 4029246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.